Related references
Note: Only part of the references are listed.Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
Stanislaw Surma et al.
CARDIOLOGY JOURNAL (2023)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effect of moderate-intensity statin therapy on plaque inflammation in patients with acute coronary syndrome: A prospective interventional study evaluated by 18F-FDG PET/CT of the carotid artery
Chan Joon Kim et al.
CARDIOLOGY JOURNAL (2020)
The PCSK9 revolution: Current status, controversies, and future directions
Bruce A. Warden et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2020)
Bempedoic acid and ezetimibe - better together
Safi U. Khan et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
Charles A. German et al.
BIODRUGS (2020)
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies
R. Scott Wright et al.
MAYO CLINIC PROCEEDINGS (2020)
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia The ORION-2 Pilot Study
G. Kees Hovingh et al.
CIRCULATION (2020)
Twice-yearly inclisiran injections halve LDL-cholesterol levels
Irene Fernandez-Ruiz
NATURE REVIEWS CARDIOLOGY (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical approach to the inflammatory etiology of cardiovascular diseases
Massimiliano Ruscica et al.
PHARMACOLOGICAL RESEARCH (2020)
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
Enrique Gallego-Colon et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
Ning Kam et al.
PHARMACOECONOMICS (2020)
Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy
Adam Hartley et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2019)
Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis center
Agnieszka Mickiewicz et al.
CARDIOLOGY JOURNAL (2019)
Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction
Jin Sup Park et al.
CARDIOLOGY JOURNAL (2019)
Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis
Zonglei Zhao et al.
MEDICINE (2019)
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
William Lang et al.
CARDIOLOGY IN REVIEW (2019)
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
Zahid Ahmad et al.
CIRCULATION (2019)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Lawrence A. Leiter et al.
DIABETES CARE (2019)
PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
NATURE REVIEWS CARDIOLOGY (2019)
Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials
Yang Wang et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
PCSK9 inhibitors in clinical practice: Expectations and reality
Zeljko Reiner
ATHEROSCLEROSIS (2018)
Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort
Michael Saborowski et al.
CARDIOLOGY JOURNAL (2018)
PCSK9 From Basic Science Discoveries to Clinical Trials
Michael D. Shapiro et al.
CIRCULATION RESEARCH (2018)
New hope for hyperlipidemia management: Inclisiran
Dhrubajyoti Bandyopadhyay et al.
JOURNAL OF CARDIOLOGY (2018)
PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Yehuda Handelsman et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses
Jillian P. Rhoads et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2018)
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Maja M. Janas et al.
TOXICOLOGIC PATHOLOGY (2018)
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
David Preiss et al.
DIABETOLOGIA (2017)
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
Sophie J. Bernelot Moens et al.
EUROPEAN HEART JOURNAL (2017)
PCSK9 and Atherosclerosis - Lipids and Beyond
Michael D. Shapiro et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs
Anastasia Khvorova
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies
Shen Gao et al.
CANADIAN JOURNAL OF CARDIOLOGY (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning
Ioanna Andreadou et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants
Jacqueline S. Dron et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
PCSK9 inhibitors: A new era of lipid lowering therapy
Rahul Chaudhary et al.
WORLD JOURNAL OF CARDIOLOGY (2017)
Local effects of human PCSK9 on the atherosclerotic lesion
Ilaria Giunzioni et al.
JOURNAL OF PATHOLOGY (2016)
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Rodrigo Alonso et al.
ATHEROSCLEROSIS (2016)
PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study
Jin M. Cheng et al.
ATHEROSCLEROSIS (2016)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Hagai Tavori et al.
CARDIOVASCULAR RESEARCH (2016)
New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications
Nabil G. Seidah
CURRENT OPINION IN LIPIDOLOGY (2016)
Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Stephan Krahenbuhl et al.
DRUGS (2016)
Inflammatory cytokines in atherosclerosis: current therapeutic approaches
Dimitris Tousoulis et al.
EUROPEAN HEART JOURNAL (2016)
Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults
Dick C. Chan et al.
HEART LUNG AND CIRCULATION (2016)
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
Wuxiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Maciej Banach et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons
K. Yadav et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2016)
Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review
Paramjit K. Sandhu et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease
Simon Barquera et al.
ARCHIVES OF MEDICAL RESEARCH (2015)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
Paul N. Hopkins et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Andreja Trpkovic et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2015)
Induction of Sustained Hypercholesterolemia by Single Adeno-Associated Virus-Mediated Gene Transfer of Mutant hPCSK9
Marta Roche-Molina et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
In Vivo Imaging of Enhanced Leukocyte Accumulation in Atherosclerotic Lesions in Humans
Fleur M. van der Valk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Intensification of Statin Therapy Results in a Rapid Reduction in Atherosclerotic Inflammation Results of a Multicenter Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Feasibility Study
Ahmed Tawakol et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
LOX-1, OxLDL, and Atherosclerosis
Angela Pirillo et al.
MEDIATORS OF INFLAMMATION (2013)
Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
Chan Joo Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
Zhihan Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions
Rogier A. van Dijk et al.
JOURNAL OF LIPID RESEARCH (2012)
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
R. Huijgen et al.
JOURNAL OF LIPID RESEARCH (2012)
The PCSK9 decade
Gilles Lambert et al.
JOURNAL OF LIPID RESEARCH (2012)
Oxidized LDL, LOX-1 and Atherosclerosis
Sona Mitra et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Oxidized LDL-induced endolysosomal phospholipidosis and enzymatically modified LDL-induced foam cell formation determine specific lipid species modulation in human macrophages
Evelyn Orso et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2011)
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
Bronwen Herbert et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
Philip J. Barter et al.
JOURNAL OF LIPID RESEARCH (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
Oxidized LDL-Activated Platelets Induce Vascular Inflammation
Karin Daub et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2010)
Origins and Mechanisms of miRNAs and siRNAs
Richard W. Carthew et al.
CELL (2009)
Regulation of TGFβ1-mediated collagen formation by LOX-1 -: Studies based on forced overexpression of TGFβ1 in wild-type and LOX-1 knock-out mouse cardiac fibroblasts
Changping Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
S. E. Humphries et al.
JOURNAL OF MEDICAL GENETICS (2006)
Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase
Feng Xia Ma et al.
JOURNAL OF LIPID RESEARCH (2006)
Pathogenesis of atherosclerosis
E Falk
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease
G Yuan et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells
DY Li et al.
CIRCULATION (2003)
Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1
DY Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Inflammation and atherosclerosis
P Libby et al.
CIRCULATION (2002)
Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells
H Kataoka et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide
L Cominacini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The oxidative modification hypothesis of atherosclerosis: Does it hold for humans?
JL Witztum et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2001)
A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1
M Kakutani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
